Novo Nordisk | NVO | Long at $86.74

The Good:

• NVO expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration's official shortage list.
  
• Just reported better-than-expected net profit in Q4 2024, amid soaring demand for its obesity drugs.
  
• Revenues for the Q4 2024 came in at $11.6 billion, up 30% compared to the same quarter in 2023.
  
• From a technical analysis perspective, hovering near my historical simple moving average which may lead to a near-term price increase due to positive earnings
  

The Bad:

• Slower growth in 2025 (16%-24% for 2025 vs 18%-26% in 2024).
  
• Chart has been on a major run since 2020 and may be due for further correction.
  

Personally, the positives outweigh the negatives given the obesity drug demand. Thus, at $86.74, NVO is in a personal buy zone.

Targets:

1. $96.00
   
2. $105.00